Pipeline
Evergreen Therapeutics is committed to advancing novel drug candidates addressing critical clinical gaps. Our pipeline targets indications including Cognitive Impairment in NPSLE, Dry Age-Related Macular Degeneration (Dry-AMD), Preeclampsia, and other conditions with persistent unmet patient needs.
Clinical Programs
Oral Tablet / Cognitive Impairment in NPSLE
EG-501 is an investigational small molecule oral tablet targeting Cognitive Impairment (CI) in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE). Systemic Lupus Erythematosus (SLE), a debilitating autoimmune disorder, involves diverse etiologies and clinical exacerbations. Cognitive impairment represents one of the most prevalent neuropsychiatric manifestations, with clinical presentations encompassing brain fog, memory deficits, aphasia, impaired verbal recall, and concentration difficulties. Approximately 56% of SLE patients develop CI within one year. No approved therapy specifically treats NPSLE-associated CI worldwide.
Clinical study demonstrated that EG-501 is a promising candidate for improving various cognitive functions, including short-and long-term memory, and attention.
Learn More About:
Oral Therapeutic / Dry Age-related Macular Degeneration (AMD) in patients exhibiting high-risk characteristics for progression to Geographic Atrophy (GA)
EG-301 is an investigational oral therapeutic targeting Dry AMD in patients exhibiting high-risk characteristics for progression to GA. GA is the advanced, blinding form of dry AMD that currently has limited treatment options. At this stage, presence of numerous medium-sized drusen or at least one large druse (>125μm diameter) and mild-moderate retinal pigment epithelium (RPE) pigmentary changes. Patients may experience subclinical to mild vision loss.
Preclinical studies demonstrate favorable efficacy and safety of EG-301. With approximate 100 million global macular disease cases (2020), Dry AMD represents about 90% of cases, creating a significant unmet medical need.
Learn More About:
Injection / Preeclampsia
EG-101 is an investigational injectable therapeutic targeting preeclampsia, affects 3–5% of pregnancies worldwide, impacting approximately 600,000 patients in China and approximately 140,000 in the US annually. The condition is characterized by hypertension, proteinuria, and multi-organ injury (primarily hepatic/renal systems). While its pathogenesis remains incompletely defined, vascular endothelial dysfunction is implicated. No approved therapeutic interventions currently exist for preeclampsia.
In preclinical models, EG-101 demonstrated efficacy in ameliorating hypertension and proteinuria. The global market for preeclampsia drugs exceeded $1 billion in 2023 and is projected to reach $2.14 billion by 2030, with a compound annual growth rate of 10%.
Learn More About:
